menu
    • menu
    [{"orgOrder":0,"company":"Celerion","sponsor":"Neuropore Therapies","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"NPT520-34","moa":"SLC22A8","graph1":"Neurology","graph2":"Phase I","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Celerion \/ Celerion"},{"orgOrder":0,"company":"Celerion","sponsor":"Prometheus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"PRA023","moa":"TL1A","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Celerion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celerion \/ Celerion","highestDevelopmentStatusID":"8","companyTruncated":"Celerion \/ Celerion"}]

    Find Clinical Drug Pipeline Developments & Deals by MTS Health Investors, LLC

    Menu

    MTS Health Investors, LLC

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Celerion

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Celerion

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRA023

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Recipient : Prometheus Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Prometheus Biosciences Commences Dosing in Multiple Ascending Dose (MAD) Portion of Ongoing Phase 1a Clinical ...

                            Details : PRA023, the company's lead product candidate, is a humanized IgG1 monoclonal antibody (mAb) that has been shown to block tumor necrosis factor (TNF)-like ligand 1A (TL1A).

                            Brand Name : PRA023

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 03, 2021

                            Lead Product(s) : PRA023

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Recipient : Prometheus Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Celerion

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Celerion

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NPT520-34

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Recipient : Neuropore Therapies

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Neuropore Completes Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed...

                            Details : The Phase 1 study was designed to evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of NPT520-34.

                            Brand Name : NPT520-34

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 13, 2020

                            Lead Product(s) : NPT520-34

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Recipient : Neuropore Therapies

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth